Announcement of providing guarantee for the holding company
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 Number: Pro 2019-010
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Announcement of Zhejiang Jianfeng Group Co., Ltd.
Providing Guarantee for Holding Subsidiaries
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Tips
● Names of Guarantees: Zhejiang Jianfeng Pharmaceutical Co., Ltd., Shanghai Beika Pharmaceutical Technology Co., Ltd. and its wholly-owned subsidiaries, Guizhou Huangpinggu Longmingchuan Cement Co., Ltd., Zhejiang Jianfeng International Trade Co., Ltd.
● To set up a financing guarantee amount: Set up a financing guarantee amount 8.8 .3 billion yuan.
● Is there any counter-guarantee in this guarantee: No
● Cumulative quantity of overdue external guarantee: No
Overview of 1. guarantee
2019 4 26 , zhejiang Jianfeng Group Co., Ltd. held thethnd meeting of the 10th Board of Directors. The company currently has nine directors, eight of whom attended the meeting in person. Director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting on his behalf and vote , complies with the relevant provisions of the "Company Law" and the company's "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the "Proposal on Providing Guarantees to Holding Subsidiaries" was deliberated and passed with 9 votes in favor, 0 votes against, and 0 abstentions.
The motion needs to be submitted to the shareholders' meeting for consideration.
Basic Information of Guaranteed 2.
1 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), registered capital 19853 Yuan, of which: the company accounts for 99.16% , registered address: on the second floor of No. 87 X02 office quality inspection building, No. 85 58 , Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province, is mainly engaged in drug research and development and production (operated with valid licenses); Import raw and auxiliary materials for production and scientific research; Imported mechanical equipment, instruments and spare parts.
, Shanghai Beika Medical Technology Co., Ltd. (hereinafter referred to as "Shanghai Beika"), with a registered capital of 2275.93 yuan, of which: the company accounts for 61.48% , registered address: Building 99 21 , 3802 , Shengang Road, Songjiang District, Shanghai, mainly engaged in: technology development, technical consultation, technical service and technology transfer in the field of medicine and chemistry; wholesale and retail of mechanical equipment, instruments and meters, edible agricultural products (excluding pig products), chemical fertilizers, feed additives, chemical raw materials and products (except dangerous goods); development and sales of pharmaceutical intermediates; import and export of goods and technologies. Shanghai Beika has three wholly-owned subsidiaries: Anhui Xinbeika Chemical Co., Ltd., Anhui Jianfeng Beika Pharmaceutical Co., Ltd., and Anhui Zhongwang Pharmaceutical Co., Ltd. 3
5000 .06 million yuan, the company accounts for 100% , registered address: Gulong Industrial Park, Huangping County, Qiandongnan Miao and Dong Autonomous Prefecture, Guizhou Province, mainly engaged in research and development, production and sales of cement products and process equipment; ordinary Portland cement and commercial concrete, cement products, limestone, artificial sand, gravel, aggregate manufacturing sales. 4
3000 .14 million yuan, of which: the company accounts for 93.33% , Jianfeng Pharmaceutical accounts for 6.67 , registered address: No. 88 , No. 119, changchun West Road, Jindong Economic Development Zone, Zhejiang, mainly engaged in: import and export of goods and technologies permitted by national laws and regulations without pre-approval; road cargo transportation; road transport station (field) operation; food management; sales of pharmaceutical intermediates, pharmaceutical equipment, etc. and online sales; national laws and policies permit Business consulting service activities; carry out international transportation agency business for import and export goods, and general cargo storage services. 3. of the above subsidiaries 2018
financial data (unit: ten thousand yuan)
|
# total 144 liabilities
|
total current liabilities
|
total bank loans
|
net assets
|
Total Operating Income
|
Net Profit Attributed to Owners of Parent Company
|
| Peak Pharmaceutical
144410.77
|
94187.16
|
88383.69
|
4600
|
50223.61
|
148762.44
|
3696.70
|
| Shanghai North Carolina
24853.30
|
10729.36
|
10685.21
|
3700
|
14123.94
|
21469.79
|
-90.77
|
| Peak International Trade
13677.85
|
11564.77
|
11462.27
|
|
2113.08 |
14443.11
|
567.82
|
| Mingchuan, Guizhou
6955.58
|
7633.27
|
7633.27
|
|
-677.70 |
0
|
-240.56
|
|
, the guarantee provided by the holding subsidiary to borrow money from financial institutions, set the following limits:
Limit (RMB 10,000)
|
| Zhejiang Jianfeng Pharmaceutical Co., Ltd.
30000
|
| Shanghai Beika Pharmaceutical technology Co., Ltd. and its wholly-owned subsidiary
20000
|
| Guizhou Huangpinggu Longmingchuan Cement Co., Ltd.
30000
|
| Zhejiang Jianfeng International Trade Co., Ltd.
8000
|
|
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page